AbbVie : ABBV

All AbbVie Articles

606 Articles

David Beren | Apr 21, 2026 at 3:34 PM EDT

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month…

David Moadel | Apr 21, 2026 at 10:30 AM EDT

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating…

Vandita Jadeja | Apr 20, 2026 at 10:37 AM EDT

Why I Can’t Stop Buying AbbVie Stock

AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The…

Vandita Jadeja | Apr 17, 2026 at 10:22 AM EDT

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record…

David Moadel | Apr 7, 2026 at 9:58 AM EDT

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan…

Vandita Jadeja | Apr 6, 2026 at 12:15 PM EDT

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two…

Lee Jackson | Apr 2, 2026 at 8:10 AM EDT

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for…

John Seetoo | Mar 27, 2026 at 11:49 AM EDT

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

John Seetoo | Mar 25, 2026 at 1:30 PM EDT

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise…

Chris MacDonald | Mar 20, 2026 at 10:02 AM EDT

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits…

Austin Smith | Mar 20, 2026 at 8:02 AM EDT

JP Morgan’s Dividend Leaders ETF Sounds Good, But The Yield Underwhelms

JPMorgan Dividend Leaders ETF (NYSEARCA:JDIV) launched in September 2024 with an appealing premise: a curated portfolio of global dividend leaders.…

Austin Smith | Mar 13, 2026 at 9:12 AM EDT

If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On

At 60 with $500,000 saved, you are closer to a workable retirement income than most people realize. The math is…

Austin Smith | Mar 11, 2026 at 12:37 PM EDT

Josh Brown: Biotech growth stocks immune to disruption risk

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech:…

Austin Smith | Mar 8, 2026 at 9:54 AM EDT

Retirees Take Note: DGRO Yields 2.4%, Has Raised Its Dividend Every Single Year for Over a Decade

DGRO has raised its annual dividend every single year since inception, through a pandemic, a rate-hiking cycle, and multiple bouts…

1 2 3 4 5 6 … 41

AbbVie : ABBV

All AbbVie Articles

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

JP Morgan’s Dividend Leaders ETF Sounds Good, But The Yield Underwhelms

If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On

Josh Brown: Biotech growth stocks immune to disruption risk

Retirees Take Note: DGRO Yields 2.4%, Has Raised Its Dividend Every Single Year for Over a Decade

Why FNGU’s 0.95% Fee Is Only Half the Hidden Cost

$10,000 Became $5,744: The Equal-Weight Rebalancing Tax That WCLD Never Discloses

Police Officers Are Missing a Social Security Change Worth Thousands a Year

Police Officers Are Missing a Social Security Change Worth Thousands a Year

Forget College? The AI Boom Is Creating a New Generation of Six-Figure Trade Jobs

Why FNGU’s 0.95% Fee Is Only Half the Hidden Cost

$10,000 Became $5,744: The Equal-Weight Rebalancing Tax That WCLD Never Discloses

AbbVie : ABBV

All AbbVie Articles

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

VIG Returned 223% Over 10 Years and Still Costs Almost Nothing

The Only 3 Growth ETFs I Would Buy and Hold Through Any Market

JP Morgan’s Dividend Leaders ETF Sounds Good, But The Yield Underwhelms

If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On

Josh Brown: Biotech growth stocks immune to disruption risk

Retirees Take Note: DGRO Yields 2.4%, Has Raised Its Dividend Every Single Year for Over a Decade

Why FNGU’s 0.95% Fee Is Only Half the Hidden Cost

$10,000 Became $5,744: The Equal-Weight Rebalancing Tax That WCLD Never Discloses

Police Officers Are Missing a Social Security Change Worth Thousands a Year

Featured Reads

Police Officers Are Missing a Social Security Change Worth Thousands a Year

Forget College? The AI Boom Is Creating a New Generation of Six-Figure Trade Jobs